Osborne Partners Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$695K Sell
28,881
-79,700
-73% -$2.08M 0.04% 144
2026
Q1
$3.05M Sell
108,581
-26,270
-19% -$699K 0.16% 112
2025
Q4
$3.36M Sell
134,851
-52,000
-28% -$1.31M 0.17% 113
2025
Q3
$4.76M Sell
186,851
-1,350
-0.7% -$33.3K 0.24% 101
2025
Q2
$4.56M Sell
188,201
-2,623
-1% -$61.2K 0.24% 105
2025
Q1
$4.84M Buy
190,824
+223
+0.1% +$5.83K 0.28% 102
2024
Q4
$5.06M Sell
190,601
-98
-0.1% -$2.66K 0.29% 103
2024
Q3
$5.52M Buy
190,699
+520
+0.3% +$15.2K 0.31% 97
2024
Q2
$5.32M Buy
190,179
+9,800
+5% +$270K 0.32% 97
2024
Q1
$5.01M Sell
180,379
-2,375
-1% -$65.9K 0.31% 99
2023
Q4
$5.26M Buy
182,754
+48
+0% +$1.45K 0.34% 91
2023
Q3
$6.06M Sell
182,706
-3,990
-2% -$141K 0.45% 76
2023
Q2
$6.85M Sell
186,696
-202
-0.1% -$7.86K 0.49% 69
2023
Q1
$7.63M Buy
186,898
+1,282
+0.7% +$55.4K 0.56% 64
2022
Q4
$9.51M Buy
185,616
+651
+0.4% +$31.2K 0.75% 46
2022
Q3
$8.09M Sell
184,965
-50,493
-21% -$2.45M 0.68% 53
2022
Q2
$12.3M Buy
235,458
+197,584
+522% +$10.1M 0.94% 32
2022
Q1
$1.96M Sell
37,874
-1,631
-4% -$84.6K 0.14% 104
2021
Q4
$2.33M Sell
39,505
-3,297
-8% -$163K 0.17% 103
2021
Q3
$1.84M Sell
42,802
-268
-0.6% -$11.9K 0.15% 105
2021
Q2
$1.69M Sell
43,070
-2,630
-6% -$102K 0.14% 108
2021
Q1
$1.66M Sell
45,700
-246,399
-84% -$8.75M 0.15% 107
2020
Q4
$10.8M Buy
292,099
+237,914
+439% +$8.73M 1.31% 18
2020
Q3
$1.89M Sell
54,185
-580
-1% -$20.3K 0.38% 72
2020
Q2
$1.7M Sell
54,765
-474
-0.9% -$16.1K 0.36% 73
2020
Q1
$1.71M Sell
55,239
-1,215
-2% -$41.4K 0.45% 68
2019
Q4
$2.1M Sell
56,454
-527
-0.9% -$18.8K 0.42% 66
2019
Q3
$1.94M Sell
56,981
-76
-0.1% -$2.76K 0.39% 71
2019
Q2
$2.35M Sell
57,057
-1,581
-3% -$62.8K 0.45% 72
2019
Q1
$2.36M Sell
58,638
-258,389
-82% -$10.3M 0.46% 68
2018
Q4
$13.1M Sell
317,027
-1,265
-0.4% -$52.5K 1.96% 8
2018
Q3
$13.3M Buy
318,292
+67
+0% +$2.58K 1.7% 9
2018
Q2
$11M Buy
318,225
+1,792
+0.6% +$61.2K 1.49% 13
2018
Q1
$10.7M Sell
316,433
-1,562
-0.5% -$53.7K 1.47% 14
2017
Q4
$10.9M Buy
317,995
+247
+0.1% +$8.42K 1.45% 16
2017
Q3
$10.8M Sell
317,748
-4,638
-1% -$149K 1.47% 16
2017
Q2
$10.3M Buy
322,386
+805
+0.3% +$25.4K 1.46% 16
2017
Q1
$10.4M Sell
321,581
-3,689
-1% -$116K 1.49% 16
2016
Q4
$10M Sell
325,270
-168
-0.1% -$5.13K 1.47% 17
2016
Q3
$10.5M Sell
325,438
-1,452
-0.4% -$48.6K 1.57% 15
2016
Q2
$10.9M Sell
326,890
-2,411
-0.7% -$76.9K 1.63% 15
2016
Q1
$9.26M Sell
329,301
-498
-0.2% -$14.2K 1.36% 18
2015
Q4
$10.1M Buy
329,799
+597
+0.2% +$18.8K 1.47% 17
2015
Q3
$9.81M Sell
329,202
-8,121
-2% -$260K 1.44% 20
2015
Q2
$10.7M Buy
337,323
+429
+0.1% +$14K 1.44% 19
2015
Q1
$11.1M Sell
336,894
-4,595
-1% -$146K 1.46% 19
2014
Q4
$10.1M Sell
341,489
-939
-0.3% -$26.9K 1.22% 28
2014
Q3
$9.61M Sell
342,428
-4,128
-1% -$116K 1.24% 28
2014
Q2
$9.76M Sell
346,556
-2,430
-0.7% -$69.3K 1.26% 28
2014
Q1
$10.6M Sell
348,986
-998
-0.3% -$29.8K 1.39% 25
2013
Q4
$10.2M Sell
349,984
-3,610
-1% -$105K 1.33% 25
2013
Q3
$9.64M Sell
353,594
-1,591
-0.4% -$43.3K 1.34% 24
2013
Q2
$9.44M Buy
+355,185
New +$9.81M 1.35% 24

Other funds holding PFE

Osborne Partners Capital Management's PFE Position: Q2 2026 in Review

Osborne Partners Capital Management reduced its Pfizer (PFE) stake by 73% in Q2 2026, selling an estimated $2.08M and leaving 28,881 shares worth $695K. The position accounts for 0.04% of the portfolio, ranked #144.

Osborne Partners Capital Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $13.3M in Q3 2018. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Osborne Partners Capital Management held 28,881 shares of Pfizer worth $695K as of Q2 2026.
  • Osborne Partners Capital Management sold 79,700 Pfizer shares in Q2 2026, an estimated $2.08M.
  • Pfizer made up 0.04% of Osborne Partners Capital Management's portfolio in Q2 2026, its #144 holding.
  • Osborne Partners Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Osborne Partners Capital Management's Pfizer position peaked at $13.3M in Q3 2018.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Osborne Partners Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.